Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

NCT00425919 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2007-12-27

No results posted yet for this study

Summary

The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

Conditions

Interventions

DRUG

PPM-204

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2007-10-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • China
  • Croatia
  • Greece
  • Hong Kong
  • India
  • Italy
  • Mexico
  • Romania
  • Russia
  • Serbia and Montenegro
  • South Africa
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425919 on ClinicalTrials.gov